Standardized incidence ratios (SIR) for selected malignancies in the intravenous abatacept cumulative period compared with external rheumatoid arthritis (RA) cohorts and the US general population. Data are SIR (95% CI). SIR are calculated by comparing the number of malignancies in the intravenous abatacept cumulative period with the expected values from the external cohorts, with SIR below 0 indicating reduced incidence with abatacept versus comparator.
| RA Cohorts | US General Population22* | |||
|---|---|---|---|---|
| BC18 | NDB20 | GPRD21 | ||
| All malignancies excluding NMSC | 0.42 (0.33, 0.51) | — | 1.11 (0.89, 1.36) | 0.99 (0.80, 1.22) |
| Lung cancer | 0.59 (0.35, 0.94) | 1.26 (0.75, 1.99) | 1.08 (0.64, 1.71) | 1.59 (0.94, 2.52) |
| Lymphoma | 0.67 (0.30, 1.27) | 0.95 (0.43, 1.80) | 1.30 (0.59, 2.46) | 2.49 (1.14, 4.73) |
| Breast cancer | 0.34 (0.18, 0.56) | 0.42 (0.23, 0.70) | 0.71 (0.39, 1.20) | 0.62 (0.34, 1.03) |
| Colorectal cancer | 0.19 (0.04, 0.54) | 0.41 (0.08, 1.19) | 0.52 (0.10, 1.51) | 0.37 (0.07, 1.07) |
↵* Data for US general population taken from the Surveillance Epidemiology and End Results database22. BC: British Columbia; NDB: National Data Bank for Rheumatic Diseases; GPRD: General Practice Research Database; NMSC: nonmelanoma skin cancer.